文献速递前列腺癌

18F-氟昔洛韦与PSMA靶向18F-DCFPyL PET/CT均检出前列腺癌局部复发

Prostate Cancer Local Recurrence Detected With Both 18F-Fluciclovine and PSMA-targeted 18F-DCFPyL PET/CT.
PubMed 文献 · Urology · 2017-06-19

本文报告一例79岁男性,前列腺切除术后前列腺特异性抗原升高,先后接受18F-氟昔洛韦PET/CT与PSMA靶向18F-DCFPyL PET/CT检查。两种显像均成功识别出同一盆腔复发病灶,但各有相对优势;本文强调这两种 increasingly 用于复发性前列腺癌显像的PET示踪剂之间的差异。

要点

  • 两例PET示踪剂均检出同一盆腔复发病灶
  • 两种示踪剂各有相对优势
  • 病例为79岁前列腺切除术后PSA升高男性

核心结论

  • 18F-氟昔洛韦与PSMA靶向18F-DCFPyL PET/CT均成功识别出同一盆腔复发病灶,但每种示踪剂各有相对优势。

研究设计与样本

  • 个案报告:一例79岁男性,前列腺切除术后前列腺特异性抗原升高,先后接受18F-氟昔洛韦PET/CT与PSMA靶向18F-DCFPyL PET/CT显像。

主要发现

  • 两种显像检查均成功识别出同一盆腔复发病灶。
  • 每种放射性示踪剂各有其相对优势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present the case of a 79-year-old man with an elevated postprostatectomy prostate-specific antigen level who was sequentially imaged with positron emission tomography/computed tomography (PET/CT) using 18F-fluciclovine followed by PSMA-targeted 18F-DCFPyL. Although both imaging tests successfully identified the same pelvic recurrence, each radiotracer had its relative merits. This case highlights the differences between these two PET radiotracers, which are increasingly being used to image men with recurrent prostate cancer.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Gorin MA, Pienta KJ, Pomper MG, et al. Prostate Cancer Local Recurrence Detected With Both 18F-Fluciclovine and PSMA-targeted 18F-DCFPyL PET/CT. Urology. 2017. PMID: 28641974. doi:10.1016/j.urology.2017.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。